<DOC>
	<DOCNO>NCT01479101</DOCNO>
	<brief_summary>The scope registry study measure chemosensitivity define pCR ( primary endpoint ) , endocrine sensitivity define partial response ( decrease long tumor diameter residual cancer burden category 1 ( RCB1 ) , primary endpoint neo-adjuvant endocrine therapy secondary endpoint neoadjuvant chemotherapy ) , metastasis-free survival relapse-free survival ( secondary endpoint ) molecular subgroup , determine establish MammaPrint , BluePrint , Targetprint Theraprint profile addition possible novel expression profile .</brief_summary>
	<brief_title>NBRST : Prospective Neo-adjuvant REGISTRY Trial</brief_title>
	<detailed_description>This prospective observational , case-only study link MammaPrint , BluePrint , TargetPrint , TheraPrint possible additional profile interest treatment response Distant Metastases Free Survival ( DMFS ) Relapse Free Survival ( RFS ) . Only patient receive neo-adjuvant therapy participate . For project , approximately 50-70 institution US invite contribute clinical patient data enrol patient MammaPrint , TargetPrint , BluePrint TheraPrint test successfully perform patient start neo-adjuvant therapy . Treatment discretion physician , adhere NCCN approve regimen recognize alternative . The clinical data enter online 4 time point ; amount four Case Report Forms ( CRFs ) . Data collect ongoing basis , first CRF must complete within 6 week MammaPrint , BluePrint , TargetPrint , TheraPrint result provide . The second CRF complete 4 week definitive surgery . CRF 3 CRF4 complete 2-3 5 year surgery . It expect enroll around 1000 patient 4 year . OBJECTIVES - Measure chemosensitivity ( defined pCR ) endocrine sensitivity ( defined decrease long tumor diameter RCB1 ) molecular subgroup determine combine MammaPrint BluePrint result . - Correlate chemosensitivity ( defined pCR ) TheraPrint Therapy Gene Assay result . - Compare local IHC FISH result ( available ) TargetPrint result . Compare three BluePrint molecular subgroup IHC-based subtype classification . - Document impact MammaPrint , TargetPrint BluePrint result treatment decision . - Assess 2-3 5 year DMFS RFS different molecular subgroup . - Measure chemosensitivity endocrine sensitivity correlation novel expression profile .</detailed_description>
	<criteria>Women histologically proven breast cancer , start schedule start neoadjuvant chemotherapy therapy neoadjuvant hormone therapy , successful MammaPrint assay Age 1890 Written inform consent Patients excisional biopsy axillary dissection Patients confirm distant metastatic disease Tumor sample ship Agendia â‰¤ 30 % tumor cell fail QA QC criterion Patients prior chemotherapy , radiotherapy , endocrine therapy treatment breast cancer Any serious uncontrolled intercurrent infection , serious uncontrolled concomitant disease</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>neo adjuvant , breast cancer</keyword>
</DOC>